{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:42:37Z","timestamp":1783539757549,"version":"3.55.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Our understanding of coronavirus disease 2019 (COVID-19) and its implications for patients with inflammatory bowel diseases (IBD) is rapidly evolving. We performed a systematic review and meta-analysis to investigate the epidemiology, clinical characteristics, and outcomes in IBD patients with COVID-19.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched PubMed, EMBASE, Cochrane Central, Clinicaltrials.gov, Web of Science, MedRxiv, and Google Scholar from inception through October 2020. We included studies with IBD patients and confirmed COVID-19. Data were collected on the prevalence, patient characteristics, pre-infection treatments for IBD, comorbidities, hospitalization, intensive care unit (ICU), admission, and death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-three studies with 51,643 IBD patients and 1449 with COVID-19 met our inclusion criteria. In 14 studies (n = 50,706) that included IBD patients with and without COVID-19, the prevalence of infection was 1.01% (95% confidence interval [CI], 0.92-1.10). Of IBD patients with COVID-19, 52.7% had Crohn\u2019s disease, 42.2% had ulcerative colitis, and 5.1% had indeterminate colitis. Nine studies (n = 687) reported outcomes according to IBD therapy received. Compared with patients on corticosteroids, those on antitumor necrosis factor (anti-TNF) therapy had a lower risk of hospitalization (risk ratio [RR], 0.24; 95% CI, 0.16-0.35; P &amp;lt; .01; I2 = 0%) and ICU admission (RR, 0.10; 95% CI, 0.03-0.37; P &amp;lt; .01) but not death (RR, 0.16; 95% CI, 0.02-1.71; P = .13; I2 = 39%). Compared with patients on mesalamine, those on antitumor necrosis factor therapy had a lower risk of hospitalizations (RR, 0.37; 95% CI, 0.25-0.54), ICU admissions (RR, 0.20; 95% CI, 0.07-0.58), and death (0.21; 95% CI, 0.04-1.00). Comparing patients on immunomodulators vs mesalamine or anti-TNF therapy, there was no difference in these outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The prevalence of COVID-19 in IBD patients was low. Use of corticosteroids or mesalamine was significantly associated with worse outcomes, whereas use of anti-TNFs was associated with more favorable outcomes. Further investigation clarifying the mechanisms of these disparate observations could help identify risk and adverse outcome-mitigating strategies for patients with IBD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izab236","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T11:08:32Z","timestamp":1635678512000},"page":"1265-1279","source":"Crossref","is-referenced-by-count":50,"title":["COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3125-2262","authenticated-orcid":false,"given":"Kartikeya","family":"Tripathi","sequence":"first","affiliation":[{"name":"University of Massachusetts Medical School, Baystate Campus , Springfield, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gala","family":"Godoy Brewer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh","family":"Thu Nguyen","sequence":"additional","affiliation":[{"name":"Vatche & Tamar Manoukian Division of Digestive Diseases, UCLA School of Medicine , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuvaraj","family":"Singh","sequence":"additional","affiliation":[{"name":"Saint Vincent Hospital , Worcester, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Saleh Ismail","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny S","family":"Sauk","sequence":"additional","affiliation":[{"name":"Vatche & Tamar Manoukian Division of Digestive Diseases, UCLA School of Medicine , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa M","family":"Parian","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology & Hepatology, Johns Hopkins University School of Medicine , Baltimore, MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkeley N","family":"Limketkai","sequence":"additional","affiliation":[{"name":"Vatche & Tamar Manoukian Division of Digestive Diseases, UCLA School of Medicine , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"2023112018213641000_CIT0001","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA."},{"key":"2023112018213641000_CIT0002","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med."},{"key":"2023112018213641000_CIT0003","volume-title":"WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China"},{"key":"2023112018213641000_CIT0004","volume-title":"Johns Hopkins Coronavirus Resource Center","author":"COVID-19 Map"},{"key":"2023112018213641000_CIT0005","author":"Data and Statistics","year":"2020"},{"key":"2023112018213641000_CIT0006","doi-asserted-by":"crossref","first-page":"212572","DOI":"10.7573\/dic.212572","article-title":"New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance","volume":"8","author":"Tripathi","year":"2019","journal-title":"Drugs Context."},{"key":"2023112018213641000_CIT0007","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10620-014-3350-9","article-title":"Environmental risk factors for inflammatory bowel diseases: a review","volume":"60","author":"Ananthakrishnan","year":"2015","journal-title":"Dig Dis Sci."},{"key":"2023112018213641000_CIT0008","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.gastro.2020.04.002","article-title":"Management of patients with Crohn\u2019s disease and ulcerative colitis during the Coronavirus disease-2019 pandemic: results of an international meeting","volume":"159","author":"Rubin","year":"2020","journal-title":"Gastroenterology."},{"key":"2023112018213641000_CIT0009","volume-title":"COVID-19 and Your Health","author":"CDC.","year":"2020"},{"key":"2023112018213641000_CIT0010","doi-asserted-by":"crossref","first-page":"S767","DOI":"10.1093\/ecco-jcc\/jjaa116","article-title":"Providing guidance during a global viral pandemic for the care of patients with inflammatory bowel disease","volume":"14","author":"Abreu","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2023112018213641000_CIT0011","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions"},{"key":"2023112018213641000_CIT0012","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.cgh.2020.04.071","article-title":"Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts","volume":"18","author":"Allocca","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112018213641000_CIT0013","doi-asserted-by":"crossref","first-page":"105061","DOI":"10.1016\/j.phrs.2020.105061","article-title":"Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: experience from humanitas center, Milan","volume":"160","author":"Allocca","year":"2020","journal-title":"Pharmacol Res."},{"key":"2023112018213641000_CIT0014","article-title":"Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease - a Danish prospective population-based cohort study","author":"Attauabi","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2023112018213641000_CIT0015","article-title":"From the American Epicenter: Coronavirus disease 2019 in patients with inflammatory bowel disease in the New York City Metropolitan Area","author":"Axelrad","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0016","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1093\/ibd\/izaa242","article-title":"Biologic therapies may reduce the risk of COVID-19 in patients with inflammatory bowel disease","volume":"26","author":"Bezzio","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0017","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/gutjnl-2020-321411","article-title":"Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study","volume":"69","author":"Bezzio","year":"2020","journal-title":"Gut."},{"key":"2023112018213641000_CIT0018","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","article-title":"Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry","volume":"159","author":"Brenner","year":"2020","journal-title":"Gastroenterology."},{"key":"2023112018213641000_CIT0019","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1093\/ibd\/izaa204","article-title":"Inflammatory bowel disease management in a major referral center during COVID-19 pandemic","volume":"26","author":"Garrido","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1053\/j.gastro.2020.05.009","article-title":"SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California","volume":"159","author":"Gubatan","year":"2020","journal-title":"Gastroenterology."},{"key":"2023112018213641000_CIT0021","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/ibd\/izaa221","article-title":"Incidence, clinical characteristics, and evolution of SARS-CoV-2 infection in patients with inflammatory bowel disease: a single-center study in Madrid, Spain","volume":"27","author":"Guerra","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0022","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJMc2009567","article-title":"Covid-19 in immune-mediated inflammatory diseases - case series from New York","volume":"383","author":"Haberman","year":"2020","journal-title":"N Engl J Med."},{"key":"2023112018213641000_CIT0023","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.imlet.2020.05.002","article-title":"Are there any association between COVID-19 severity and immunosuppressive therapy?","volume":"224","author":"Hormati","year":"2020","journal-title":"Immunol Lett."},{"key":"2023112018213641000_CIT0024","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2020.06.044","article-title":"Adherence of infusible biologics during the time of COVID-19 among patients with inflammatory bowel disease: a Nationwide Veterans Affairs Cohort Study","volume":"159","author":"Khan","year":"2020","journal-title":"Gastroenterology."},{"key":"2023112018213641000_CIT0025","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/ibd\/izaa212","article-title":"Management of inflammatory bowel disease and COVID-19 in New York City 2020: the epicenter of IBD in the first epicenter of the global pandemic","volume":"26","author":"Kornbluth","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0026","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1053\/j.gastro.2020.05.066","article-title":"Baseline disease activity and steroid therapy stratify risk of COVID-19 in patients with inflammatory bowel disease","volume":"159","author":"Lukin","year":"2020","journal-title":"Gastroenterology."},{"key":"2023112018213641000_CIT0027","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.dld.2020.06.007","article-title":"Low frequency of COVID-19 in inflammatory bowel diseases","volume":"52","author":"Marafini","year":"2020","journal-title":"Dig Liver Dis."},{"key":"2023112018213641000_CIT0028","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1053\/j.gastro.2020.08.046","article-title":"Asymptomatic severe acute respiratory syndrome Coronavirus 2 infection in patients with inflammatory bowel disease under biologic treatment","volume":"159","author":"Norsa","year":"2020","journal-title":"Gastroenterology."},{"key":"2023112018213641000_CIT0029","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.gastro.2020.04.043","article-title":"Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque Country (Spain)","volume":"159","author":"Rodr\u00edguez-Lago","year":"2020","journal-title":"Gastroenterology."},{"key":"2023112018213641000_CIT0030","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/apt.15804","article-title":"2019 Novel Coronavirus disease (COVID-19) in patients with inflammatory bowel diseases","volume":"52","author":"Taxonera","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112018213641000_CIT0031","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/ibd\/izaa195","article-title":"Inflammatory bowel diseases in Egypt during the COVID-19 pandemic","volume":"26","author":"Eltabbakh","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0032","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1053\/j.gastro.2020.06.003","article-title":"Risk of severe Coronavirus disease 2019 in patients with inflammatory bowel disease in the United States: a multicenter research network study","volume":"159","author":"Singh","year":"2020","journal-title":"Gastroenterology."},{"key":"2023112018213641000_CIT0033","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1093\/ibd\/izaa244","article-title":"COVID-19 in patients with inflammatory bowel disease: a single-center observational study in Northern Italy","volume":"26","author":"Vigan\u00f2","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0034","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/apt.15897","article-title":"Letter: immunotherapy in IBD patients in a SARS-CoV-2 endemic area","volume":"52","author":"Waggershauser","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112018213641000_CIT0035","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000508740","article-title":"Mild COVID-19 symptoms in an Infliximab-treated ulcerative colitis patient: can ongoing anti-TNF therapy protect against the viral hyperinflammatory response and avoid aggravated outcomes?","volume":"36","author":"Abdullah","year":"2020","journal-title":"Visc Med."},{"key":"2023112018213641000_CIT0036","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/gutjnl-2020-321760","article-title":"Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds","volume":"70","author":"Bezzio","year":"2021","journal-title":"Gut."},{"key":"2023112018213641000_CIT0037","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1093\/ibd\/izaa186","article-title":"A challenging colectomy for acute severe ulcerative colitis complicated by COVID-19","volume":"26","author":"Di Ruscio","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0038","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1093\/ibd\/izaa275","article-title":"SARS-CoV-2 infection and dual-biologic therapy for Crohn\u2019s disease","volume":"26","author":"Dimopoulos","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0039","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000508161","article-title":"Recovery from COVID-19 pneumonia in a patient with acute severe colitis","volume":"5","author":"Garcia","year":"2020","journal-title":"Inflamm Intest Dis."},{"key":"2023112018213641000_CIT0040","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s10620-020-06299-y","article-title":"Going viral: management of IBD in the era of the COVID-19 pandemic","volume":"65","author":"Gutin","year":"2020","journal-title":"Dig Dis Sci."},{"key":"2023112018213641000_CIT0041","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1093\/ibd\/izaa093","article-title":"Case report of a SARS-CoV-2 infection in a patient with ulcerative colitis on Tofacitinib","volume":"26","author":"Jacobs","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0042","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaa105","article-title":"Potential INHIBITION of COVID-19-driven pneumonia by immunosuppressive therapy and anti-TNF\u03b1 antibodies: a case report","author":"Kunisaki","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2023112018213641000_CIT0043","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jclinpath-2020-206912","article-title":"Acute kidney injury caused by COVID-19 in a patient with Crohn\u2019s disease treated with adalimumab","volume":"74","author":"Lenti","year":"2021","journal-title":"J Clin Pathol."},{"key":"2023112018213641000_CIT0044","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000000814","article-title":"The many faces of COVID-19: atypical presentation of COVID-19 in a patient with Crohn\u2019s disease with acute diarrhea leading to severe hypovolemic hyponatremia-a case report","volume":"115","author":"Mansoor","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"2023112018213641000_CIT0045","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.dld.2020.07.022","article-title":"Safe administration of corticosteroids in severe ulcerative colitis and active SARS-CoV2 infection","volume":"52","author":"Mayer","year":"2020","journal-title":"Dig Liver Dis."},{"key":"2023112018213641000_CIT0046","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/gutjnl-2020-321183","article-title":"A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis","volume":"69","author":"Mazza","year":"2020","journal-title":"Gut."},{"key":"2023112018213641000_CIT0047","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1093\/ibd\/izaa175","article-title":"Prolonged duration of SARS-CoV-2 viral positivity in a Crohn\u2019s disease patient","volume":"26","author":"Navaneethan","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0048","article-title":"The course of SARS-COV2 infection was not severe in a Crohn\u2019s patient who administered maintenance anti-TNF therapy overlapping the early pre-symptomatic period of infection","volume":"9","author":"Okeke","year":"2020","journal-title":"Antibodies Basel Switz."},{"key":"2023112018213641000_CIT0049","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/ibd\/izaa109","article-title":"Management of acute severe ulcerative colitis in a pregnant woman with COVID-19 infection: a case report and review of the literature","volume":"26","author":"Rosen","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0050","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1136\/gutjnl-2020-321240","article-title":"COVID-19 infection in Crohn\u2019s disease under treatment with adalimumab","volume":"69","author":"Tursi","year":"2020","journal-title":"Gut."},{"key":"2023112018213641000_CIT0051","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/ecco-jcc\/jjaa076","article-title":"Impact of anti-TNF\u03b1 antibodies on the risk of covid-19 and its severity in patients with inflammatory bowel diseases","volume":"14","author":"Tursi","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2023112018213641000_CIT0052","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.14309\/ajg.0000000000000725","article-title":"Temporal improvement of a COVID-19-positive Crohn\u2019s disease patient treated with bismuth subsalicylate","volume":"115","author":"Wolf","year":"2020","journal-title":"Am J Gastroenterol."},{"key":"2023112018213641000_CIT0053","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ibd\/izaa278","article-title":"Immunosuppressive therapy and risk of COVID-19 infection in patients with inflammatory bowel diseases","volume":"27","author":"Burke","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2023112018213641000_CIT0054","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/2050640620972602","article-title":"Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"9","author":"Singh","year":"2021","journal-title":"United European Gastroenterol J."},{"key":"2023112018213641000_CIT0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","volume":"70","author":"Ungaro","year":"2021","journal-title":"Gut."},{"key":"2023112018213641000_CIT0056","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet."},{"key":"2023112018213641000_CIT0057","first-page":"657","article-title":"What to do when biologic agents are not working in inflammatory bowel disease patients","volume":"11","author":"Dalal","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2023112018213641000_CIT0058","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front Immunol."},{"key":"2023112018213641000_CIT0059","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"2023112018213641000_CIT0060","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2020.02.009","article-title":"Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases","volume":"18","author":"Beaugerie","year":"2020","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112018213641000_CIT0061","article-title":"Risk perception of COVID-19 is associated with biologic usage in patients with inflammatory bowel disease","author":"Shah","year":"2021"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/8\/1265\/53599854\/izab236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/8\/1265\/53599854\/izab236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T20:52:05Z","timestamp":1700513525000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/28\/8\/1265\/6412576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":61,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,10,27]]},"published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izab236","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2021,10,27]]}}}